Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data - Trial NCT04985448
Access comprehensive clinical trial information for NCT04985448 through Pure Global AI's free database. This phase not specified trial is sponsored by Chengdu Kanghong Biotech Co., Ltd. and is currently Enrolling by invitation. The study focuses on Retinopathy of Prematurity. Target enrollment is 1000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Chengdu Kanghong Biotech Co., Ltd.
Timeline & Enrollment
N/A
Aug 01, 2021
Dec 01, 2021
Primary Outcome
Main effectiveness indicators,Main safety indicators
Summary
This study is a retrospective, multi-center real world study. The real world data comes from
 the electronic medical record system and disease database of the research centers .The
 patient's demographic information, disease information, clinical treatment status, efficacy
 evaluation and adverse events and so on will be collected and evaluated by applicability of
 the data, generated an analysis data set. Use the causal inference method of statistical
 analysis to observe the effectiveness and safety of intravitreal injection of Conbercept, and
 explore the effectiveness and safety of different doses in the treatment of retinopathy of
 prematurity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04985448
Non-Device Trial